摘要
为分析肝动脉化疗栓塞(TACE)联合射频消融(RFA)治疗肝癌的临床效果及影响预后质量的因素,以52例原发性肝癌患者为研究对象(观察组),采用TACE联合RFA治疗,观察患者的1~3年存活率、中位生存期、不良反应和影响疗效的因素。结果为:TACE联合RFA治疗组患者的1~3年存活率分别为90.4%,80.8%,44.2%,中位生存时间为(2.5±0.2)年;临床治愈或明显好转率、好转及稳定率明显高于对照组,恶化率明显低于对照组;不良反应分别为疼痛2例、肝功能损害1例、胃肠道反应2例;多因素分析显示TNM分期是影响生存期的独立危险因素。TACE联合射频消融治疗肝癌的疗效确切、安全性高、患者的生存率高,可作为非切除治疗肝癌方法。患者的TNM分期是术后生存率的独立因素,联合治疗时需要结合患者的治疗指征才能提高治疗效果。
Objective ： to analyze clinical effects and factors on prognosis quality of treating hepatocellular carci- noma by transeatheter arterial ehemoembolization （TACE） combined with radiofrequency ablation （RFA）. Method：52 cases of primary liver cancer patients were treated with TACE combined with RFA, the survival rate,median survival time,adverse reaction and the factors influencing the efficacy of 1 -3 were observed. Results ：TACE combined with RFA treatment group of patients with 1 -3 years survival rate was 90.4% , 80.8% ,44.2% ,the median survival time was （2.5 ＋0.2） years, clinical curative rate, physical ability scores, adverse reactions respectively were higher than the control group, while the worsening rate was obvi- ously lower,there were two cases with adverse reaction,one case with hepatic dysfunctionpain,two cases with gastrointestinal reaction;multivariate analysis showed that TNM stage was an independent risk factor for effect on survival. Conclusion：TACE combined with RFA for treatment of liver cancer was effective and safe,the survival rate of patients was high and it can be used as a non - resection liver cancer treatment method. TNM stage was an independent factor for postoperative survival rate and patients＇therapeutic index must be taken into consideration during combination therapy to improve treatment effect.
出处
《湖北理工学院学报》
2017年第1期54-58,共5页
Journal of Hubei Polytechnic University
